Correlation
The correlation between PRLB and VRTX is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
PRLB vs. VRTX
Compare and contrast key facts about Proto Labs, Inc. (PRLB) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PRLB or VRTX.
Performance
PRLB vs. VRTX - Performance Comparison
Loading data...
Key characteristics
PRLB:
0.41
VRTX:
0.05
PRLB:
1.11
VRTX:
0.09
PRLB:
1.15
VRTX:
1.01
PRLB:
0.24
VRTX:
-0.09
PRLB:
1.55
VRTX:
-0.23
PRLB:
14.02%
VRTX:
9.47%
PRLB:
58.76%
VRTX:
28.66%
PRLB:
-91.22%
VRTX:
-91.77%
PRLB:
-85.05%
VRTX:
-13.48%
Fundamentals
PRLB:
$897.34M
VRTX:
$114.53B
PRLB:
$0.60
VRTX:
-$3.83
PRLB:
1.71
VRTX:
2.65
PRLB:
1.80
VRTX:
10.32
PRLB:
1.37
VRTX:
6.93
PRLB:
$499.21M
VRTX:
$11.10B
PRLB:
$221.43M
VRTX:
$9.55B
PRLB:
$46.82M
VRTX:
-$76.30M
Returns By Period
In the year-to-date period, PRLB achieves a -3.79% return, which is significantly lower than VRTX's 11.02% return. Over the past 10 years, PRLB has underperformed VRTX with an annualized return of -5.88%, while VRTX has yielded a comparatively higher 13.43% annualized return.
PRLB
-3.79%
6.21%
-7.82%
23.92%
-8.24%
-21.52%
-5.88%
VRTX
11.02%
-11.20%
-3.76%
1.35%
17.77%
9.20%
13.43%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
PRLB vs. VRTX — Risk-Adjusted Performance Rank
PRLB
VRTX
PRLB vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Proto Labs, Inc. (PRLB) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
PRLB vs. VRTX - Dividend Comparison
Neither PRLB nor VRTX has paid dividends to shareholders.
Drawdowns
PRLB vs. VRTX - Drawdown Comparison
The maximum PRLB drawdown since its inception was -91.22%, roughly equal to the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for PRLB and VRTX.
Loading data...
Volatility
PRLB vs. VRTX - Volatility Comparison
The current volatility for Proto Labs, Inc. (PRLB) is 12.26%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 13.43%. This indicates that PRLB experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
PRLB vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Proto Labs, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PRLB vs. VRTX - Profitability Comparison
PRLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Proto Labs, Inc. reported a gross profit of 55.70M and revenue of 126.21M. Therefore, the gross margin over that period was 44.1%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.
PRLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Proto Labs, Inc. reported an operating income of 4.53M and revenue of 126.21M, resulting in an operating margin of 3.6%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.
PRLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Proto Labs, Inc. reported a net income of 3.60M and revenue of 126.21M, resulting in a net margin of 2.9%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.